Data Sharing and Privacy in Pharmaceutical Studies

Author(s): Rufan Chen, Yi Zhang, Zuochao Dou, Feng Chen, Kang Xie, Shuang Wang*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 7 , 2021

Become EABM
Become Reviewer
Call for Editor


Adverse drug events have been a long-standing concern for the wide-ranging harms to public health, and the substantial disease burden. The key to diminish or eliminate the impacts is to build a comprehensive pharmacovigilance system. Application of the “big data” approach has been proved to assist the detection of adverse drug events by involving previously unavailable data sources and promoting health information exchange. Even though challenges and potential risks still remain. The lack of effective privacy-preserving measures in the flow of medical data is the most important Accepted: one, where urgent actions are required to prevent the threats and facilitate the construction of pharmacovigilance systems. Several privacy protection methods are reviewed in this article, which may be helpful to break the barrier.

Keywords: Drug use, pharmacovigilance, data sharing, data privacy, ethics, policy, social netowork.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 02 April, 2021
Page: [911 - 918]
Pages: 8
DOI: 10.2174/1381612827999210112204732
Price: $65

Article Metrics

PDF: 427